Compass Pathways

Compass Pathways Cash & Equivalents

The Cash & Short-Term Investments of Compass Pathways (CMPS) as of Oct 29, 2026 is 149.61 M USD. In the previous year, Cash & Short-Term Investments was 165.08 M USD — a change of -9.37% (lower).

Cash & Equivalents

149.61 MUSD

YoY

-9.37%

Last updated:

Cash & Short-Term Investments of Compass Pathways is 2025 149.61 M USD. Cash & Short-Term Investments of Compass Pathways was 2024 165.08 M USD. It decreases by -9.37% lower compared to the previous year.

The Compass Pathways Cash & Equivalents history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash & Equivalents
Date
Cash & Equivalents
Jan 1, 2018
22.91 M USD
Jan 1, 2019
24.97 M USD
Jan 1, 2020
190.33 M USD
Jan 1, 2021
273.24 M USD
Jan 1, 2022
143.21 M USD
Jan 1, 2023
220.20 M USD
Jan 1, 2024
165.08 M USD
Jan 1, 2025
149.61 M USD
The Compass Pathways Cash & Equivalents history
YEARCash & EquivalentsYoY
149.61 MUSD-9.37%
165.08 MUSD-25.03%
220.20 MUSD+53.76%
143.21 MUSD-47.59%
273.24 MUSD+43.57%
190.33 MUSD+662.34%
24.97 MUSD+8.99%
22.91 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Compass Pathways Stock analysis

What does Compass Pathways do? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compass Pathways stock

Cash & Short-Term Investments of Compass Pathways is 149.61 M USD in 2025.

Cash & Short-Term Investments of Compass Pathways changed from 165.08 M USD to 149.61 M USD, representing a -9.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash & Short-Term Investments Compass Pathways since 2006 – with annual values, charts, and detailed analysis.

Cash and equivalents represent the most liquid assets on the balance sheet, available for immediate use or short-term obligations.

Cash & Short-Term Investments's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cash & Short-Term Investments's Compass Pathways historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Compass Pathways

All Key Metrics — Compass Pathways